首页> 外文期刊>Yonsei Medical Journal >How Many Valid Measurements Are Necessary to Assess Liver Fibrosis Using FibroScan? in Patients with Chronic Viral Hepatitis? An Analysis of Subjects with at Least 10 Valid Measurements
【24h】

How Many Valid Measurements Are Necessary to Assess Liver Fibrosis Using FibroScan? in Patients with Chronic Viral Hepatitis? An Analysis of Subjects with at Least 10 Valid Measurements

机译:使用FibroScan评估肝纤维化需要多少次有效测量?在慢性病毒性肝炎患者中?具有至少10个有效度量的主题分析

获取原文
       

摘要

Purpose Using FibroScan? to obtain a reliable liver stiffness measurement (LSM) may require more than 10 valid measurements (VMs), according to the manufacturer's recommendations. However, this requirement lacks scientific evidence in support thereof. We investigated the minimal number of VMs required to assess liver fibrosis without significant loss of accuracy in patients with chronic hepatitis B (CHB) and C (CHC) and predictors of discordance between LSM and liver biopsy (LB). Materials and Methods Between January 2005 and December 2009, we prospectively enrolled 182 patients with CHB and 68 patients with CHC who were to undergo LB and LSM before starting antiviral treatment. Only LSMs with at least 10 VMs were considered reliable. The Batts and Ludwig scoring system was used for histologic assessment. Results The mean age and body mass index were 46.0 years and 23.4 kg/m2 in patients with CHB and 49.7 years and 23.1 kg/m2 in those with CHC, respectively. The median elasticity scores from the first 3, first 5, and all VMs taken significantly predicted fibrosis stages ≥F2 and F4 (all p 0.05 by DeLong's method). Alanine aminotransferase (ALT) was the only predictor of discordance in fibrosis stage as estimated by the median elasticity score from the first 3 VMs and by LB in patients with CHB, whereas no significant predictor was identified in those with CHC. Conclusion After comparison of patients who had more than 10 valid measurements for LSM, three VMs may be enough to assess liver fibrosis using LSM without significant loss of accuracy in patients with CHC and patients with CHB. However, ALT should be considered when interpreting LSM for patients with CHB.
机译:目的使用FibroScan?根据制造商的建议,要获得可靠的肝硬度测量值(LSM),可能需要进行10次以上的有效测量值(VMs)。但是,此要求缺乏支持它的科学证据。我们调查了在慢性乙型肝炎(CHB)和丙型肝炎(CHC)患者中评估肝纤维化所需的最少数量的VM,而准确性没有显着降低,并且预测了LSM和肝活检(LB)之间的不一致。材料与方法在2005年1月至2009年12月之间,我们前瞻性地招募了182例CHB患者和68例CHC患者,这些患者在开始抗病毒治疗之前接受了LB和LSM治疗。仅具有至少10个VM的LSM被认为是可靠的。 Batts and Ludwig评分系统用于组织学评估。结果CHB患者的平均年龄和体重指数分别为46.0岁和23.4 kg / m 2 ,而CHC患者的平均年龄和体重指数分别为49.7岁和23.1 kg / m 2 。前3个,前5个以及所有VM的中位数弹性评分均显着预测了≥F2和F4的纤维化分期(根据DeLong方法,所有p均≥0.05)。根据丙型肝炎患者前3个VM的中位弹性评分和LB估计,丙氨酸氨基转移酶(ALT)是纤维化阶段不一致的唯一预测因子​​,而在CHC患者中未发现明显的预测因子。结论在对具有10项以上有效LSM测量值的患者进行比较后,使用3台VM足以评估使用LSM进行的肝纤维化,而不会对CHC患者和CHB患者造成明显的准确性损失。但是,在为CHB患者解释LSM时应考虑ALT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号